BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the Sidoti December Small Cap Conference, taking place virtually from December 6-7, 2023. Details are as follows:
Sidoti December Small Cap Conference
Format: Company Presentation
Date and Time: Wednesday, December 6, 2023, from 12:15 pm - 12:45 pm EST
Location: Virtual
A live webcast of the presentation can be accessed from the Investors section of the Athira website or by clicking here.. An archived replay will be available for at least 30 days following the event.
Athira Pharma will also host virtual one-on-one meetings with investors on Wednesday, December 6 and Thursday, December 7. To register for the conference and schedule a one-on-one meeting, please visit https://sidoti.com/events.
About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological disease by advancing its pipeline of therapeutic candidates targeting the HGF neurotrophic system for Alzheimer’s and Parkinson’s disease, Dementia with Lewy bodies, and amyotrophic lateral sclerosis. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on X, formerly known as Twitter, and Instagram.
Investor & Media Contact:
Julie Rathbun
Athira Pharma
This email address is being protected from spambots. You need JavaScript enabled to view it.
206-769-9219
| Last Trade: | US$0.58 |
| Daily Change: | -0.02 -3.33 |
| Daily Volume: | 53,788 |
| Market Cap: | US$22.430M |
November 07, 2024 October 22, 2024 September 17, 2024 September 03, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
